Sorry, you need to enable JavaScript to visit this website.

Activity of a nitroxylated analog of daunorubicin, ruboxyl, in B-lymphoproliferative disorders

TitleActivity of a nitroxylated analog of daunorubicin, ruboxyl, in B-lymphoproliferative disorders
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2001
AuthorsSeminara, P., Franchi F., Konovalova N., Pioli Claudio, Rossetti R., Tubani L., Doria G., and Fanelli F.R.
JournalActa Haematologica
Volume105
Pagination77-82
ISSN00015792
Keywords80 and over, adult, aged, animal cell, animal experiment, animal model, Animals, Antibiotics, Antineoplastic, article, B-Lymphocytes, bone marrow suppression, bone marrow toxicity, cardiotoxicity, Cells, clinical trial, Cultured, Daunorubicin, daunorubicin derivative, Disease-Free Survival, Dose-Response Relationship, Drug, drug effect, Drug Evaluation, drug screening, human, Humans, Inbred C57BL, Lymphocyte Count, lymphoproliferative disease, Lymphoproliferative Disorders, male, Mice, Middle Aged, mouse, multiple myeloma, nonhuman, Perthes disease, Pilot Projects, pilot study, Preclinical, priority journal, Remission Induction, ruboxyl, Spleen, T-Lymphocytes, Waldenstrom Macroglobulinemia
Abstract

A nitroxylated analog of daunorubicin, ruboxyl (RBX), showed low toxicity but significant lympholytic effect in preclinical evaluations. A series of studies in vitro and in animals demonstrate that RBX is a putative agent in the treatment of many neoplasms. We report the results of a study in mice in which RBX showed selective B-lymphocyte immunosuppression. On the basis of this experience, RBX was administered to 3 patients with multiple myeloma and two patients with Waldenström's disease. The results of this pilot clinical study show that this compound has good activity and low myelotoxicity and cardiotoxicity, but seems to be characterized by a threatening immunosuppressive effect. Copyright © 2001 S. Karger AG, Basel.

Notes

cited By 4

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0034932598&doi=10.1159%2f000046538&partnerID=40&md5=78746489eb3f4393cb0c4be6c3a75218
DOI10.1159/000046538
Citation KeySeminara200177